Exenatide is a Glucagon-Like Peptide-1 (GLP-1) analog improving fasting and post-prandial glycaemia, approved in patients treated with a combination of sulfonylureas and metformin and not achieving good metabolic control. This retrospective cohort study compared the efficacy and safety of exenatide in unselected patients with outcomes of FDA trials and other uncontrolled published studies. Exenatide was prescribed in 108 patients between April 2008 and December 2009, 80% of the patients were treated with 10 μg of exenatide twice daily. Mean follow up was 4.5 months for the 1st follow up. Changes in HbA1c (−1.1%), BMI (−1.1) and fasting glucose (−0.61 g/l) from baseline were significant, and coherent with controlled trials. 32% of patients had at least one side effect, often gastro intestinal. 23% stopped the treatment, a quarter (1/4) of which for inefficacity. Patients with a higher BMI (>40) (n = 29) at baseline did not show a better response in HbA1c or weight. Results at the second follow-up show a slight tendency of rising on HbA1c, BMI and fasting blood glucose. Finally, a third follow-up at a mean of 17 months is available for 11 patients, which shows stability in HA1c, BMI and fasting glucose. In our experience, Exenatide was safe and effective in reducing HbA1c and weight in patients who were able to tolerate it. Our results are close to results published elsewhere. There are still gaps in the literature on exenatide, especially on the long term effect, which need to be assessed by more publications.
INTRODUCTION
Treatment of type 2 diabetes is challenging because of the progressive nature of the disease. A combination of insulin resistance and insulin deficiency occurs at different stages in time, with a marked link with obesity. Half of type 2 diabetes patients require more than one oral anti-diabetic drug (OAD) within 3 years from diagnosis and combination oral therapy with or without insulin therapy within 6 to 9 years from diagnosis [1] . Exenatide was the first incretin mimetic agent released in France, in April 2008. It was approved for use in combination with metformin and sulfonylureas for patients not achieving adequate glycaemic control on maximal tolerated dose of OAD. Exenatide is an incretin and a Glucagon-Like Peptide −1 (GLP-1) analog improving fasting and post-prandial glycaemia by inducing glucosedependant insulin secretion and suppressing glucagon secretion from the pancreas. It also delays gastric emptying and induces early satiety [2] . Exenatide was first FDA (Food and Drug Administration) Approved in November 2006 after the publication of 3 short term studies conducted by the manaufacturer [3] [4] [5] . The objective of this study was to compare the efficacy and safety of exenatide in unselected patients with outcomes of FDA trials and other uncontrolled published studies [6] [7] [8] [9] .
METHODS
This retrospective cohort study used the medical database of our community hospital diabetes department, ranging from April 2008 to December 2009. Permission to review patients' data was obtained from the local institutional review board. Medical record was detailed at baseline for age, sex, type and duration of diabetes, associated treatment for diabetes before starting exenatide, weight, height and BMI, HbA1c and fasting glycaemia, self monitoring of blood glucose and self-reported episodes of hypoglycaemia. Follow-up was divided in 3 periods: 1 st period: first six months, 2 nd period: six to twelve months, 3 rd period: more than 12 months. We evaluated number lost to follow-up, exenatide dose effectively done, mean follow-up in months, changes in weight, BMI, HbA1c and fasting glycaemia, associated
RESULTS
Exenatide was prescribed in 108 patients between April 2008 and December 2009. Main data are shown in Table 1 . Follow-up in the 1 st period is available for 91 patients (16% lost to follow-up). Medical baseline records of "lost to follow-up patients" did not differ significantly from patients with at least one follow-up (data not shown). 80% of the patients were treated with 10 µg of exenatide twice daily. Mean follow up was 4.5 months for this group. Changes in HbA1c (−1.1%), BMI (−1.1) and fasting glucose (−0.61 g/l) from baseline were significant. 32% of patients had at least one side effect, most of them of the gastro intestinal type. 23% stopped the treatment , 1/4 of which for inefficacity. Patients with a higher BMI (>40) (n = 29) at baseline did not show a better response in HbA1c or loss of weight. A second follow-up is available for 38 patients, at 10.5 months. 17 patients will stop the treatment at this stage, 9 for inefficacity. HbA1c, BMI and fasting blood glucose show a slight tendency of rising. Finally, a third follow-up at a mean of 17 months is available for 11 patients, which shows stability in HbA1c, BMI and fasting glucose.
DISCUSSION
In our experience, Exenatide was safe and effective in reducing HbA1c and weight in patients who were able to tolerate it. The results observed are very similar to the one published in 2 randomised trials of 6 months duration resumed in Table 2 . There is no controlled data for a longer period, but extension studies of controlled 6 months studies show maintenance of the control of blood glucose at one year. Gain in HbA1c and weight were similar at 6 months and one year: -0.8% to 1% in HbA1c and -2.5 to -3.6 kgs. Reductions in weight and HbA1c with exenatide are even greater when uncontrolled studies are taken into account (data shown in Table 3 ). Therefore, we didn't observe the same results for the weight in our population, but the limited number of subjects with a long follow up is probably responsible for this difference, with no statistical significance. Limitations inherent to retrospective manner are important, because some side effects can be omitted inadvertently for example, despite the use of a standardised query form and few patients have a long follow up. Inclusion of patients completing the follow up can induce a favoring bias. In our study, patients lost to follow up had no clinical differences compared to patients with at least one follow up. Long term data are difficult to obtain, for example in the one year follow up study published par M. Buysschaert and al. 77 patients on 299 included stopped the treatment before the end of the study and 12 months data was available for 94 patients over all. Data on a longer duration (2 year extension open label study) concern a limited number of very selected patients (approximatively 25 % of patients initially included in 6 months controlled versus placebo studies [9] ). Most of controlled studies were funded by the pharmaceutical industry or had at least one author affiliated with industry, and there is empirical data suggesting that industryfunded studies are potentially biased towards the agent 
CONCLUSION
In summary, efficacy and tolerability of exenatide in "real care" setting are similar than in short term controlled studies, but data in the long term are still lacking. Patients offered to be treated with exenatide often ask their practitioner "for how long should I use this treatment?" and there is still no answer to that.
